This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Biosynthesis of Conjugate Veterinary Vaccine
The biological approach is an emerging technology in which the coupling of polysaccharides to proteins is performed by the bacteria themselves. BioVenic provides the services for conjugate veterinary vaccine development by biological methods, and we will explore the new technology with you to develop veterinary vaccines.
Our Services
In the development of conjugate veterinary vaccines using biosynthesis methods, preparation for production is accomplished by induced expression of the engineered strains and purification. BioVenic has established a technology platform that encompasses comprehensive services required throughout the development process.
Fig.1 Process for the biological preparation of conjugate veterinary vaccines.
Engineered Strain Construction
The first step in the biological development of conjugate veterinary vaccines is the construction of Escherichia coli which lacks genes for O-antigen ligase and autopolysaccharide synthesis. The absence of O-antigen ligase blocked the synthesis of LPS, and free OPS was produced in the bacteria. BioVenic has launched a variety of strain genome editing services to help knock out the gene responsible for encoding O antigen ligase, after knocking out the gene, the bacteria cannot synthesize complete lipopolysaccharide, and the virulence is significantly reduced and plenty of free O polysaccharide appears in the peristomal.
- Homologous Recombination
- Bacterial Artificial Chromosome
- CRISPR System
Expression Vector Construction
BioVenic provides expression vector construction services, including gene synthesis and gene cloning to clone genes responsible for encoding glycosyltransferases and carrier proteins into plasmid vectors. BioVenic also provides purification and validation services, such as purification of glycoprotein products using gel filtration chromatography, detection of protein expression by staining and protein immunoblotting after SDS-PAGE, and detection of their sugar content by the anthrone-concentrated sulfuric acid method. Here are the detailed service contents.
| Expression Vector Construction | Construct an expression vector containing the gene cluster responsible for synthesizing the target polysaccharide, the carrier protein, and the glycosyltransferase. |
| Introduction to Engineered Strain | Introduce the expression vector into an engineered strain. This strain is modified to accommodate a specific sequence (known as the glycosylation motif) recognized by the glycosyltransferase on the carrier protein. |
| Induced Expression | Induce the expression of the components contained in the expression vector in the engineered strain. This includes the carrier protein, glycosyltransferase, and the gene cluster responsible for target polysaccharide synthesis. |
| Polysaccharide Transfer | Under the catalytic action of glycosyltransferase, the heterologous target polysaccharides onto the carrier protein. This transfer is guided by the specific glycosylation motif incorporated into the carrier protein. |
| Glycoprotein Purification | Purify the obtained glycoprotein (comprising the carrier protein with attached target polysaccharides) to isolate and obtain a pure, functional final sample. |
Conjugate Veterinary Vaccine Development Services
The development of conjugate veterinary vaccines involves a number of important aspects, and BioVenic provides other related vaccine development services.
BioVenic provides in vivo and in vitro assessment services to test the effectiveness of new technologies. Meanwhile, during the development process of biosynthesis, polysaccharides are biocatalytically coupled to fixed glycosylation sites, so the linkage is clearly defined and the ratio of sugars to proteins is determined, which is conducive to batch consistency.
The introduction of carrier proteins for conjugation with polysaccharide antigens has resulted in a certain increase in immunogenicity, and biosynthesis of conjugate veterinary vaccines leads to an increase in vaccine safety compared to chemical methods.
BioVenic provides strict quality control, which will make your conjugate vaccines more stable and high-quality finished products.
Why Choose Us?
With biosynthesis as an emerging technology, BioVenic helps you on your path to new conjugate veterinary vaccine development with extensive experience.
BioVenic offers a variety of advanced gene editing platforms to construct engineered strains.
BioVenic conducts in-depth research on glycosyltransferases in order to expand the application of biosynthesis of conjugate veterinary vaccines.
BioVenic is confident to explore the mystery of the biosynthesis method with you and apply it to conjugate veterinary vaccine development. Our first-class team and excellent technology platform to help you in the research and development smoothly, to get the finished product of the vaccine you expect. Contact us now and let's work together for animal health!